Publications by authors named "Hgm Harry Heijerman"
Objectives: To describe the long-term effects of ivacaftor (Kalydeco®) in individuals with cystic fibrosis (CF) on body mass index (BMI), body composition (BC), pulmonary function (PF), resting energy expenditure (REE), and exercise capacity (EC) after ≥12 months of treatment.
Working Hypothesis: BMI, lean and fat mass, PF, and EC will increase and REE will decrease after treatment.
Study Design: Observational study.